Previous 10 | Next 10 |
NEW YORK , Oct. 11, 2019 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City , is investigating: Dova Pharmaceuticals, Inc ( DOV...
Biotech is in the doldrums. The SPDR S&P Biotech ETF declined 18% in the past six months, and money continues to flow out of the sector. While several biotechs managed to IPO in September and October , it's not all roses. ADC Therapeutics pulled its plans to list citing market...
Stock market participants displayed a positive attitude on Thursday, apparently buoyed by signs that leaders of the U.S. and China will at least keep meeting in an effort to resolve their differences on trade issues. Major benchmark indexes were up by around half a percent on the day, and with e...
NEW YORK, Oct. 10, 2019 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Ra Pharmaceuticals, Inc. (NASDAQ: RARX) to UCB S.A. (“UCB”) for $48.00 per share is fair to Ra shareholders. On behalf of Ra shareholders, Halp...
Gainers : Ra Pharmaceuticals, Inc. (NASDAQ: RARX ) +100% . OncoSec Medical Incorporated (NASDAQ: ONCS ) +34% . ProPetro Holding Corp. (NYSE: PUMP ) +22% . Mereo BioPharma Group plc (NASDAQ: MREO ) +21% . Bed Bath & Beyond (NASDAQ: BBBY ) +20% . Caladrius Biosciences (NASDAQ: CLBS ...
Shares of Ra Pharmaceuticals (NASDAQ: RARX) , a clinical-stage biopharmaceutical company focused on rare diseases , jumped 101% as of 10:56 a.m. EST on Thursday. The huge move is a response to the news that Ra has agreed to be acquired by UCB (NASDAQOTH: UCBJF) , a global biopharmace...
Ra Pharmaceuticals (NASDAQ: RARX ) +102% on being acquired by UCB SA. More news on: Ra Pharmaceuticals, Inc., OncoSec Medical Incorporated, Bed Bath & Beyond Inc., Stocks on the move, Read more ...
Will enhance UCB’s leadership potential in myasthenia gravis by adding zilucoplan , a peptide inhibitor of complement component 5 (C5) currently in phase 3, to the UCB pipeline alongside to UCB’s rozanolixizumab , an FcRn targeting antibody also in phase 3 Will enrich U...
Ra Pharmaceuticals (NASDAQ: RARX ) initiates dosing in the RAISE study, its pivotal, Phase 3 clinical trial evaluating zilucoplan for the treatment of generalized myasthenia gravis (gMG). More news on: Ra Pharmaceuticals, Inc., Healthcare stocks news, Read more ...
Top-line data from the Phase 3 RAISE study expected in early 2021 Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced the initiation of dosing in the RAISE study, its global, pivotal, Phase 3 clinical trial evaluating zilucoplan for the treatment of generalized myasthenia gravis (gM...
News, Short Squeeze, Breakout and More Instantly...
Ra Pharmaceuticals Inc. Company Name:
RARX Stock Symbol:
NASDAQ Market:
Ra Pharmaceuticals Inc. Website:
Ra Pharmaceuticals, Inc. (Nasdaq:RARX) is joining forces with 30 million healthcare advocates around the world for the 13 th Annual Rare Disease Day ® , an awareness day dedicated to elevating public understanding of rare diseases and calling attention to the special challenges people l...
Enrollment ongoing in Phase 3 clinical trial of zilucoplan in gMG, with top-line results expected in early 2021 First patient dosed in Phase 2 clinical trial of zilucoplan in IMNM, with top-line results expected in the second half of 2020 IND cleared by FDA for the HEALEY ALS Plat...
ZUG, Switzerland and CAMBRIDGE, Mass., Feb. 26, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced it proposes to elect Doug Treco, Ph.D. to its Board of Direc...